SMTL ID : 7bh9.1

SARS-CoV-2 RBD-62 in complex with ACE2 peptidase domain

Coordinates

PDB Format Compare

Method

ELECTRON MICROSCOPY

Oligo State

hetero-1-1-mer

Ligands

1 x ZN: ZINC ION(Non-covalent)

ZN.1: 3 residues within 4Å: Chain A: H.358, H.362, E.386 3 PLIP interactions: 3 interactions with chain A Metal complexes: A:H.358, A:H.362, A:E.386

3 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)

NAG.2: 5 residues within 4Å: Chain A: H.401, S.404, D.527, S.529, N.530 3 PLIP interactions: 3 interactions with chain A Hydrogen bonds: A:S.404, A:S.404, A:N.530 NAG.3: 1 residues within 4Å: Chain A: N.74 1 PLIP interactions: 1 interactions with chain A Hydrogen bonds: A:K.10 NAG.4: 4 residues within 4Å: Chain A: N.37, T.39, N.42, Q.324 2 PLIP interactions: 2 interactions with chain A Hydrogen bonds: A:N.42, A:Q.324

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Zahradnik, J. et al., SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. Nat Microbiol (2021)

Release Date

2021-02-17

Peptides

Angiotensin-converting enzyme 2: A
Spike protein S1: B

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
E

Angiotensin-converting enzyme 2

Spike protein S1